CEO: Ensuring EpiPen access is ‘the core of Mylan’s mission’

The company is releasing a generic version of its product, along with offering a savings card that gives patients up to $300 off the drug. Will it be enough to fix its PR woes?

Ragan Insider Premium Content
Ragan Insider Content

On Monday, the company issued a press release announcing that a generic version of its product—used to treat anaphylaxis, a severe allergic reaction—would be available in several weeks.

It’s the second move in the past week to quell unrelenting criticism over the drug’s current list price of $600. In 2008, the auto-injector cost roughly $100. Last week, Mylan announced a savings card, which covers up to $300 of the EpiPen 2-Pak.

The New York Times reported:

The new move could help mollify critics, though some are likely to point out that even at $300, the generic would still be triple the price of the EpiPen in 2007, when Mylan acquired the product and began steadily raising its price from around $100 for a pair, with the price increases accelerating in recent years.

To read the full story, log in.
Become a Ragan Insider member to read this article and all other archived content.
Sign up today

Already a member? Log in here.
Learn more about Ragan Insider.